XC-130
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is taken orally. The drug is a dopamine D 2 receptor partial agonist, a dopamine D 3 receptor antagonist, an α 1A -adrenergic receptor antagonist, and a serotonin 5-HT 1B , 5-HT 2A , and 5-HT 2B receptor antagonist. Its potency as a dopamine D 2 receptor agonist is similar to that of lisuride. XC-130 produces antiparkinsonian-like effects in animals.
Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D 3 agonism), vasoconstriction (related to α 1A -adrenergic and 5-HT 1B agonism), hallucinogenic effects (related to 5-HT 2A agonism), and cardiac valvulopathy (related to 5-HT 2B agonism). It has a notably longer elimination half-life than the relatively short-acting lisuride.
The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile. XC-130 is under development by Xoc Pharmaceuticals. As of November 2022, it is in phase 1/2 clinical trials. The chemical structure of XC-130 does not yet appear to have been disclosed.
XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is taken orally. The drug is a dopamine D 2 receptor partial agonist, a dopamine D 3 receptor antagonist, an α 1A -adrenergic receptor antagonist, and a serotonin 5-HT 1B , 5-HT 2A , and 5-HT 2B receptor antagonist. Its potency as a dopamine D 2 receptor agonist is similar to that of lisuride. XC-130 produces antiparkinsonian-like effects in animals.
Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D 3 agonism), vasoconstriction (related to α 1A -adrenergic and 5-HT 1B agonism), hallucinogenic effects (related to 5-HT 2A agonism), and cardiac valvulopathy (related to 5-HT 2B agonism). It has a notably longer elimination half-life than the relatively short-acting lisuride.
The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile. XC-130 is under development by Xoc Pharmaceuticals. As of November 2022, it is in phase 1/2 clinical trials. The chemical structure of XC-130 does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338600850 under CC BY-SA 4.0; modifications have been made.